X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    New Delivery Path Brings To Light Efficacy of Immunotherapy

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    New Delivery Path Brings To Light Efficacy of Immunotherapy

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Market Moves

Morphogenesis announces USDA-sanctioned clinical trial for promising equine cancer vaccine

Yuvraj_pawp by Yuvraj_pawp
5th September 2014
in Market Moves

Morphogenesis Inc., the biotechnology firm developing ImmuneFx™, a cancer vaccine that has improved the longevity and quality of life for dogs, cats and horses, announces that a formal equine clinical trial for the direct injection form of the vaccine will begin later this month at a large equine facility in Missouri.

 

Pat Lawman, PhD., co-founder and CEO of Morphogenesis Inc., said that melanoma is a problem in grey horses and can be slow-growing or malignant. There is currently no USDA-approved treatment for equine melanoma.

 

Expected to last about a year, the clinical trial is designed to precisely assess the efficacy and safety of the ImmuneFx™ cancer vaccine in horses.

 

“We have had some major successes in reducing equine melanoma in the cases we have treated to date, and depending on the results, this formal study will statistically and scientifically establish the reliability of the therapy,” said Dr. Lawman.

ImmuneFx™ has been used to treat more than 20 different types of cancers in dogs, cats and horses. In fact, the personalized form of ImmuneFx™ is currently being used by veterinarians across the U.S.

 

In this equine study, Kris Hennessy, Ph.D, DVM, of Hennessy Research, will be testing an off-the-shelf form of ImmuneFx™ vaccine that is directly injected into the melanoma lesions of the horses. Successful study outcomes will allow Morphogenesis to obtain a commercial license from the USDA to sell the injectable form of ImmuneFx™ for treatment of equine melanoma.

 

Plans call for the personalized form of ImmuneFx™ to be in human clinical trials early next year. All the company’s activities, including its clinical trials, are investor-funded.

 

ABOUT MORPHOGENESIS

 

Morphogenesis Inc. (www.morphogenesis-inc.com) is a privately-held biotechnology company that is conducting ground-breaking research in the rapidly growing cell therapy, biologics and tissue engineering fields. The company has received financial support from grantors and private investors around the world.

 

Morphogenesis holds more than 20 U.S. issued and pending patents that cover rare cell identification and separation technologies, stem cell growth factors and cancer vaccines. Morphogenesis is currently focused on its multi-indication therapeutic cancer vaccine, ImmuneFx™, which educates the patient’s own immune system to attack tumor cells throughout the body without damaging normal cells or systems.

 

ABOUT THE IMMUNOTHERAPY MARKET

 

Several leading authorities project the annual therapeutic cancer vaccine market to expand to $8 billion within the next six years. Immunotherapy revenues worldwide are predicted to reach $35 billion in 10 years. Experts predict that within the next 10 years, 50-60 percent of cancer treatments will involve immunotherapy.

SOURCE Morphogenesis Inc.

Previous Post

Luye Pharma Acquired 57.98% Stake of Beijing Jialin Pharmaceutical

Next Post

Astellas Receives Notification from FDA of Acceptance of Filing of Isavuconazole NDA for the Treatment of Invasive Aspergillosis and Invasive Mucormycosis

Related Posts

Featured

SVB Collapse And Its Implications On Biotechnology Sector

18th March 2023
Featured

US President Looks To Double The Drugs For Price Negotiation

18th March 2023
$118bn Sales By 2026 Is What Japanese Pharma Can Expect
Featured

$118bn Sales By 2026 Is What Japanese Pharma Can Expect

2nd March 2023
Featured

Bioavailability Enhancement Market Projects CAGR of 11%

28th February 2023
Grünenthal to buy NebidoTM testosterone treatment from Bayer for €500m
Market Moves

Grünenthal to buy NebidoTM testosterone treatment from Bayer for €500m

18th July 2022
Could The Long Deckline In Biotechnology M&A Be Ending
Featured

Could The Long Deckline In Biotechnology M&A Be Ending

16th July 2022
Next Post

Astellas Receives Notification from FDA of Acceptance of Filing of Isavuconazole NDA for the Treatment of Invasive Aspergillosis and Invasive Mucormycosis

Latest News

Drug Development

New Delivery Path Brings To Light Efficacy of Immunotherapy

1st April 2023
Cathay Cargo signs global airline partnership with Tower Cold Chain
Packaging & Logistic

Cathay Cargo signs global airline partnership with Tower Cold Chain

31st March 2023
Quotient Sciences completes integration of drug substance into Translational Pharmaceutics Platform
Facilities & Operation

£277m Funding Set To Benefit UK Life Sciences Manufacturing

31st March 2023
Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In